Treatment of heart rhythm disturbances associated with SARS-CoV-2 infection with anti-inflammatory drugs
https://doi.org/10.30629/0023-2149-2023-101-12-665-674
Abstract
Publications regarding cardiac arrhythmias associated with the new coronavirus infection (COVID-19) focus primarily on the high prevalence and symptoms of this complication. We have not found any studies on the specific treatment of arrhythmias associated with SARS-CoV2, since a standard therapeutic approach is probably implied. This observation describes a series of cases of various cardiac arrhythmias that occurred against the background of acute COVID-19 and were treated with anti-inflammatory, but not antiarrhythmic drugs. The cases are united by the occurrence of acute SARS-CoV-2 infection, the connection of relapses with inflammation symptoms, as well as the effectiveness of therapy with the main classes of anti-inflammatory drugs. A narrative review of the literature provides the rationale for the inflammatory theory of arrhythmias and sets the stage for discussion about how to integrate differentially anti-inflammatory drugs into the treatment regimen of such patients.
About the Authors
Z. N. Sukmarova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Zulfiya N. Sukmarova — Candidate of Medical Sciences, Researcher
115522, Moscow
E. G. Zotkin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Evgeny G. Zotkin — Doctor of Medical Sciences, First Deputy Director
115522, Moscow
References
1. Granier M., Massin F., Pasquié J.L. Pro- and anti-arrhythmic effects of anti-inflammatory drugs. Antiinflamm Antiallergy Agents. Med. Chem. 2013;12(1):83–93. DOI: 10.2174/1871523011312010010
2. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011;91(1):265–325. DOI: 10.1152/physrev.00031.2009
3. Siripanthong B., Nazarian S., Muser D., Deo R., Santangeli P., Khanji M.Y., Cooper L.T. Jr., Chahal C.A.A. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020;17(9):1463–1471. DOI: 10.1016/j.hrthm.2020.05.001
4. Sukmarova Z., Martynenko T., Bryklya E., Fedorova E. Pericarditis as a new highly specific symptom of SARS-CoV-2: a case-control study. Materials of the Congress “Radiology 2021” (In Russi an)
5. Zhan Y., Yue H., Liang W., Wu Z. Effects of COVID-19 on arrhythmia. J. Cardiovasc. Dev. Dis. 2022;9(9):292. DOI: 10.3390/jcdd9090292
6. Coromilas E.J., Kochav S., Goldenthal I., Biviano A., Garan H., Goldbarg S., Kim J.H., Yeo I., Tracy C., Ayanian S. et al. Worldwide survey of COVID-19 Associated Arrhythmias. Circ. Arrhythm. Electrophysiol. 2021;14:e009458. DOI: 10.1161/CIRCEP.120.009458
7. Cavigli L., Frascaro F., Turchini F., Mochi N., Sarto P., Bianchi S., Parri A., Carraro N., Valente S., Focardi M. et al. A prospective study on the consequences of SARS-CoV-2 infection on the heart of young adult competitive athletes: Implications for a safe return-to-play. Int. J. Cardiol. 2021;336:130–136. DOI: 10.1016/j.ijcard.2021.05.042
8. Musika ntow D.R., Turagam M.K., Sartori S. et al. Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza. JACC Clin. Electrophysiol. 2021;7(9):1120–1130. DOI: 10.1016/j.jacep.2021.02.009
9. Patone M., Mei X.W., Handunnetthi L., Dixon S., Zaccardi F., Shankar-Hari M., Watkinson P., Khunti K., Harnden A., Coupland C.A.C. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 2022;28:410–422. DOI: 10.1038/s41591-021-01630-0
10. Sangpornsuk N., Rungpradubvong V., Tokavanich N., Srisomwong S., Ananwattanasuk T., Teerawongsakul P., Kerr S.J., Su wanwalaikorn M., Jongnarangsin K., Chokesuwattanaskul R. Arrhythmias after SARS-CoV-2 Vaccination in Patients with a Cardiac Implantable Electronic Device: A Multicenter Study. Biomedicines. 2022;10:2838. DOI: 10.3390/biomedicines10112838
11. Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P. et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283–288. DOI: 10.1038/s41586-021-03631-y
12. Blagova O., Varionchik N., Zaidenov V., Savina P., Sarkisova N. Anti-heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID-19. Eur. J. Immunol. 2021;51:893–902. DOI: 10.1002/eji.202048930
13. Friedrichs K., Klinke A., Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med. 2011;17(10):556–563. DOI: 10.1016/j.molmed.2011.05.007
14. Lazzerini P.E., Capecchi P.L., Laghi-Pasini F. Systemic inflammation and arrhythmic risk: Lessons from rheumatoid arthritis. Eur. Heart J. 2017;38:1717–1727. DOI: 10.1093/eurheartj/ehw208
15. Korompoki E., Gavriatopoulou M., Hicklen R.S., Ntanasis-Stathopoulos I., Kastritis E., Fotiou D., Stamatelopoulos K., Terpos E., Kotanidou A., Hagberg C.A. et al. Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. J. Infect. 2021;83:1–16. DOI: 10.1016/j.jinf.2021.05.004
16. Ryu K., Li L., Khrestian C.M., Matsumoto N., Sahadevan J., Ruehr M.L., Van Wagoner D.R., Efimov I.R., Waldo A.L. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am. J. Physiol. Heart Circ. Physiol. 2007;293(2):H1231–41. DOI: 10.1152/ajpheart.00607.2006
17. Maesen B., Nijs J., Maessen J., Allessie M., Schotten U. Postoperative atrial fibrillation: a maze of mechanisms. Europace. 2012;14(2):159–174. DOI: 10.1093/europace/eur208
18. Makhnir EF, Goloukhova LM, Golovko EV. Violations of a rhythm of heart at patients with rheumatoid arthritis as display of a rheumatoid heart trouble. Bulletin of the Russian state medical university. 2009;7:45–8. (In Russian)
19. Novikova D.S., Popkova T.V., Gerasimov A.N., Volkov A.V., Nasonov E.I. Silent myocardial ischemia and cardiac rhythm disturbances in women with rheumatoid arthritis. The Clinician. 2013;7(3–4):31–39. (In Russian) DOI: 10.17650/1818-8338-2013-3-4-31-39
20. Peretto G., Sala S., Rizzo S., Palmisano A., Esposito A., De Cobelli F., Campochiaro C., De Luca G., Foppoli L., Dagna L., Thiene G., Basso C., Della Bella P. Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. J. Am. Coll. Cardiol. 2020;75(9):1046–1057. DOI: 10.1016/j.jacc.2020.01.036
21. Tian S., Xiong Y., Liu H., Niu L., Guo J., Liao M., Xiao S.Y. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod. Pathol. 2020;33(6):1007–1014. DOI: 10.1038/s41379-020-0536-x
22. Disertori M., Rigoni M., Pace N., Casolo G., Mase M., Gonzini L., Lucci D., Nollo G., Ravelli F. Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis. JACC Cardiovasc. Imaging. 2016;9:1046–1055. DOI: 10.1016/j.jcmg.2016.01.033
23. Sukmarova Z.N., Saidova M.A., Ovchinnikov Yu.V. Exudative pericarditis in the pathogenesis of cardiac arrhythmias in COVID-19: a series of clinical cases. Cardiovascular therapy and prevention. 2022;21(2):3021. (In Russian) DOI: 10.15829/1728-8800-2022-3021
24. Sukmarova Z.N., Ovchinnikov Yu.V., Larina O.M., Lependin S.O., Afonina O.V., Gromov A.I. Mitral valve chordae avulsion in highly trained men early after COVID-19. A clinical cases series. Sports medicine: science and practice. 2022;12(1):77–85. (In Russian) DOI: 10.47529/2223-2524.2022.1.2
25. Pagé P.L., Plumb V.J., Okumura K., Waldo A.L. A new animal model of atrial flutter. J. Am. Coll. Cardiol. 1986;8(4):872–879. DOI: 10.1016/s0735-1097(86)80429-6.11.
26. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., Wildevuur C.R., Eijsman L., Trouwborst A., Hack C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96(10):3542–3548. DOI: 10.1161/01.cir.96.10.3542
27. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., Tracy R.P., Van Wagoner D.R., Psaty B.M., Lauer M.S., Chung M.K. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006–10. DOI: 10.1161/01.CIR.0000103131.70301.4F
28. Myocardial Inflammation/Myocarditis After COVID-19 mRNA Booster Vaccination. C. Mueller. Oral presentation. URL: https://esc365.escardio.org/presentation/25541412.
29. Sukmarova Z.N., Ovchinnikov Yu.V., Gudima G.O., Ibragimova F.M., Afonina O.V., Machkalyan K.E. Increased pericardial echogenity in recipients of SARS-CoV-2 vaccines. Infectious diseases. 2021;19(4):43–50. (In Russian) DOI: 10.20953/1729-9225-2021-4-43-50
30. Ho K.M., Tan J.A. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation. 2009;119(14):1853–1866. DOI: 10.1161/CIRCULATIONAHA.108.848218
31. De Caterina R., Ruigómez A., Rodríguez L.A. Long-term use of anti-inflammatory drugs and risk of atrial fibrillation. Arch. Intern. Med. 2010;170(16):1450–1455. DOI: 10.1001/archinternmed.2010.305
32. Ammirati E., Frigerio M., Adler E.D., Basso C., Birnie D.H., Brambatti M., Friedrich M.G., Klingel K., Lehtonen J., Moslehi J.J., Pedrotti P., Rimoldi O.E., Schultheiss H.P., Tschöpe C., Cooper L.T. Jr, Camici P.G. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ. Heart Fail. 2020;13(11):e007405. DOI: 10.1161/CIRCHEARTFAILURE.120.007405
33. Nidorf S.M., Fiolet A.T.L., Mosterd A., Eikelboom J.W., Schut A., Opstal T.S.J., The S.H.K., Xu X.F., Ireland M.A., Lenderink T., Latchem D., Hoogslag P., Jerzewski A., Nierop P., Whelan A., Hendriks R., Swart H., Schaap .J, Kuijper A.F.M., van Hessen M.W.J., Saklani P., Tan I., Thompson A.G., Morton A., Judkins C., Bax W.A., Dirksen M., Alings M., Hankey G.J., Budgeon C.A., Tijssen J.G.P., Cornel J.H., Thompson P.L.; LoDoCo2 Trial investigators. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 2020;383(19):1838–1847. DOI: 10.1056/NEJMoa2021372
34. Bouabdallaoui N., Tardif J.C., Waters D.D., Pinto F.J., Maggioni A.P., Diaz R., Berry C., Koenig W., Lopez-Sendon J., Gamra H., Kiwan G.S., Blondeau L., Orfanos A., Ibrahim R., Grégoire J.C., Dubé M.P., Samuel M., Morel O., Lim P., Bertrand O.F., Kouz S., Guertin M.C., L’Allier P.L., Roubille F. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur. Heart J. 2020;41(42):4092–4099. DOI: 10.1093/eurheartj/ehaa659
35. Sukmarova Z.N., Simonenko V.B., Nasonov E.L. Treatment of pericarditis with colchicine, interleukin-1 antagonists, immuno suppressants. Clinical medicine. 2023;101(1):6–17. (In Russian) DOI: 10.30629/0023-2149-2023-101-1-6-17
36. Bakele M., Joos M., Burdi S., Allgaier N., Pöschel S., Fehren bacher B., Schaller M., Marcos V., Kümmerle-Deschner J., Rieber N., Borregaard N., Yazdi A., Hector A., Hartl D. Localization and functionality of the inflammasome in neutrophils. J. Biol. Chem. 2014;289(8):5320–5329. DOI: 10.1074/jbc.M113.505636
37. Imazio M., Brucato A., Ferrazzi P., Pullara A., Adler Y., Barosi A., Caforio A.L., Cemin R., Chirillo F., Comoglio C., Cugola D., Cumetti D., Dyrda O., Ferrua S., Finkelstein Y., Flocco R., Gandino A., Hoit B., Innocente F., Maestroni S., Musumeci F., Oh J., Pergolini A., Polizzi V., Ristic A., Simon C., Spodick D.H., Tarzia V., Trimboli S., Valenti A., Belli R., Gaita F; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fi brillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016–1023. DOI: 10.1001/jama.2014.11026
38. Imazio M., Brucato A., Ferrazzi P., Rovere M.E., Gandino A., Cemin R., Ferrua S., Belli R., Maestroni S., Simon C., Zingarelli E., Barosi A., Sansone F., Patrini D., Vitali E., Trinchero R., Spodick D.H., Adler, Y. Investigators, C. Colchi cine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124(21):2290–2295. DOI: 10.1161/CIRCULATIONAHA.111.026153
39. Shvartz V., Le T., Enginoev S., Sokolskaya M., Ispiryan A., Shvartz E., Nudel D., Araslanova N., Petrosyan A., Donakanyan S., Chernov I., Bockeria L., Golukhova E. Colchicine in Cardiac Surgery: The COCS randomized clinical trial. J. Cardiovasc. Dev. Dis. 2022;9(10):363. DOI: 10.3390/jcdd9100363
40. Sukmarova Z.N., Simonenko V.B., Nasonov E.L. Treatment of pericarditis with anti-inflammatory drugs. Clinical medicine. 2022;100(11–12):509–519. (In Russian) DOI: 10.30629/0023-2149-2022-100-11-12-509-519
41. Zhang J., Ding E.L., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619–1632. DOI: 10.1001/jama.296.13.jrv60015
42. Schmidt M., Christiansen C.F., Mehnert F., Rothman K.J., Sørensen H.T. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. DOI: 10.1136/bmj.d3450
43. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1328. DOI: 10.1136/bmj.332.7553.1302
44. Rosenberg E.S., Dufort E.M., Udo T., Wilberschied L.A., Kumar J., Tesoriero J., Weinberg P., Kirkwood J., Muse A., DeHovitz J., Blog D.S., Hutton B., Holtgrave D.R., Zucker H.A. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493–2502. DOI: 10.1001/jama.2020.8630
Review
For citations:
Sukmarova Z.N., Zotkin E.G. Treatment of heart rhythm disturbances associated with SARS-CoV-2 infection with anti-inflammatory drugs. Clinical Medicine (Russian Journal). 2023;101(12):665-674. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-12-665-674
Views:
342
Email this article 